A Study to Assess the Safety and Tolerability of Single and Multiple Doses of AZD4831 in Healthy Male Subjects

Summary

This is a Phase I, first-in-human (FIH) study to assess the safety, tolerability, pharmacokinetics (PK) and Pharmacodynamics (PD) of AZD4831 after single and multiple ascending doses in healthy male subjects

Timeline

Start

2016-06

Primary completion

2016-10

Completion

2016-10

Publications

• Sunnaker M, Leander J, Ericsson H. Population Pharmacokinetics of the Novel Myeloperoxidase Inhibitor Mitiperstat. Pharmacol Res Perspect. 2026 Jun;14(3):e70259. doi: 10.1002/prp2.70259.

Drugs

Indications